Shares of Marksans Pharma slipped 4 percent intraday Thursday after USFDA issued Form 483 with eight observations.
USFDA has concluded inspection at Goa Facility which took place between February 25 and March 6, 2019, resulting in a Form 483 with eight observations.
None of these observations are considered either critical or repetitive in nature. Company is highly confident of closing these expeditiously and remains committed to global standards of quality & compliance, company said in release.
The share touched its 52-week high Rs 40.55 and 52-week low Rs 22.00 on 04 September, 2018 and 20 February, 2019, respectively.
Currently, it is trading 34.9 percent below its 52-week high and 20 percent above its 52-week low.
For more details click here – https://www.ways2capital.com
This post first appeared on After Italy Verdict Gold Trades Higher On Safe-haven Demands; Silver Down, please read the originial post: here